Trikafta

(asked on 7th January 2020) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the timetable is for Trikafta being made available on the NHS for cystic fibrosis sufferers.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 15th January 2020

It is a condition of the agreement reached between NHS England and NHS Improvement and Vertex that the company will submit its full portfolio of cystic fibrosis medicines, including its new triple therapy, marketed in the United States as Trikafta to National Institute for Health and Care Excellence (NICE) for appraisal.

NICE has begun work for the appraisal and further information is available at the following link:

https://www.nice.org.uk/guidance/proposed/gid-ta10566

NICE will invite the company to provide an evidence submission immediately after the triple therapy has been formally referred to its work programme, expected in February.

The triple therapy does not yet have a marketing authorisation for use in the United Kingdom and the dates for licensing have not yet been confirmed. Subject to licensing, in order to recommend the triple therapy for routine National Health Service funding, NICE will need to be assured that Vertex have priced it at a level that is fair to both the NHS and UK taxpayer. In the period leading up to that, NICE will work extensively with the company and other stakeholders in putting the best possible evidence submission to its independent advisory committee.

Reticulating Splines